SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma informs about analyst meet

18 Nov 2022 Evaluate
Aurobindo Pharma has informed that Yugandhar Puvvala, Chief Executive Officer of Eugia Pharma Specialities, a wholly owned subsidiary of the Company, will be interacting with officials of Abu Dhabi Investment Authority and Lion Global Investors, at corporate office today November 17, 2022, between 4.00 pm to 5.00 pm. No unpublished price sensitive information (UPSI) is intended to be discussed during the interactions. 

The above information is a part of company’s filings submitted to BSE.

Aurobindo Pharma Share Price

1379.25 -6.40 (-0.46%)
20-Apr-2026 10:30 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1670.30
Dr. Reddys Lab 1237.90
Cipla 1238.95
Zydus Lifesciences 941.85
Lupin 2332.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×